160. Erickson S.J. et al. Hypocarbia in the ventilated preterm infant and its effect on intraventricular haemorrhage and bronchopulmonary dysplasia // J. Paediatr. Child Health. 2002. Vol. 38, № 6. P. 560–562.
161. Cools F. et al. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants // Cochrane Database Syst. Rev. 2015. № 3.
162. Ambalavanan N. et al. PaCO2 in surfactant, positive pressure, and oxygenation randomised trial (SUPPORT) // Arch. Dis. Child. Fetal Neonatal Ed. 2015. Vol. 100, № 2. P. F145–F149.
163. Bellù R. et al. Opioids for newborn infants receiving mechanical ventilation // Cochrane Database Syst. Rev. 2021. № 3.
164. Barrington K.J. Management during the first 72h of age of the periviable infant: An evidence-based review // Semin. Perinatol. 2014. Vol. 38, № 1. P. 17–24.
165. Mihatsch W. et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Calcium, phosphorus and magnesium // Clin. Nutr. 2018. Vol. 37, № 6. P. 2360–2365.
166. van Goudoever J.B. et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Amino acids // Clin. Nutr. 2018. Vol. 37, № 6. P. 2315–2323.
167. Joosten K. et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Energy // Clin. Nutr. 2018. Vol. 37, № 6. P. 2309–2314.
168. Mesotten D. et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Carbohydrates // Clin. Nutr. 2018. Vol. 37, № 6. P. 2337–2343.
169. Jochum F. et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Fluid and electrolytes // Clin. Nutr. 2018. Vol. 37, № 6. P. 2344–2353.
170. Lapillonne A. et al. ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition: Lipids // Clin. Nutr. 2018. Vol. 37, № 6. P. 2324–2336.
171. Клинические рекомендации. Нормальная беременность. 2020.
172. Клинические рекомендации. Инфекция мочевых путей при беременности. 2022.
173. Hitchins M. et al. Treatment of persistent methicillin-susceptible Staphylococcus aureus bacteremia and presumed osteomyelitis with oxacillin and ertapenem in a premature neonate // Pharmacotherapy. 2023. Vol. 43, № 1. P. 96–99.
174. Akers S.M. et al. Clearance of persistent staphylococcus aureus bacteremia in a preterm neonate with the use of combination cefazolin and ertapenem // J. Pediatr. Pharmacol. Ther. 2020. Vol. 25, № 6. P. 547–551.
175. Shabaan A.E. et al. Conventional Versus Prolonged Infusion of Meropenem in Neonates With Gram-negative Late-onset Sepsis: A Randomized Controlled Trial // Pediatr. Infect. Dis. J. 2017. Vol. 36, № 4. P. 358–363.
176. Lee S.Y.R., Chow C.B. Safe use of imipenem/cilastatin in a neonatal intensive care unit // Pediatr. Int. 1998. Vol. 40, № 2. P. 186–187.
177. Shafiq N, Malhotra S, Gautam V et al. Evaluation of evidence for pharmacokinetics-pharmacodynamics-based dose optimization of antimicrobials for treating Gram-negative infections in neonates. // Indian J Med Res. 2017. Vol. 145, № 3. P. 299-316.
178. Reed M.D. et al. Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life // Antimicrob. Agents Chemother. 1990. Vol. 34, № 6. P. 1172–1177.
179. Stuart RL, Turnidge J G.M. Safety of imipenem in neonates. // Pediatr Infect Dis J. 1995. Vol. 14, № 9. P. 803–805.
180. Dao K. et al. Dosing strategies of imipenem in neonates based on pharmacometric modelling and simulation // J. Antimicrob. Chemother. 2022. Vol. 77, № 2. P. 457–465.
181. Freij BJ, McCracken GH Jr, Olsen KD T.N. Pharmacokinetics of imipenem-cilastatin in neonates. // Antimicrob Agents Chemother. 1985. Vol. 27, № 4. P. 431–435.
182. Bégué PC, Baron S, Challier P, Fontaine JL L.G. Pharmacokinetic and clinical evaluation of imipenem/cilastatin in children and neonates // Scand J Infect Dis Suppl. 1987. Vol. 52. P. 40–45.
183. Yoshizawa K, Ikawa K, Ikeda K, Ohge H M.N. Population pharmacokinetic-pharmacodynamic target attainment analysis of imipenem plasma and urine data in neonates and children. // Pediatr Infect Dis J. 2013. Vol. 32, № 11. P. 1208-1216.
184. James J., Mulhall A., de Louvois J. Ceftriaxone-clinical experience in the treatment of neonates // J. Infect. 1985. Vol. 11, № 1. P. 25–33.
185. Chen D., Ji Y. New insights into Citrobacter freundii sepsis in neonates // Pediatr. Int. 2019. Vol. 61, № 4. P. 375–380.
186. Van Reempts PJ, Van Overmeire B, Mahieu LM V.K. Clinical experience with ceftriaxone treatment in the neonate. // Chemotherapy. 1995. Vol. 41, № 4. P. 316–322.
187. Silverman W.A. A.D.H. A controlled clinical trial of effects of water mist on obstructive respiratory signs, death rate and necropsy findings among premature infants. // Pediatrics. 1956. Vol. 17, № 1. P. 1–10.